The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
5112
June 9, 2025
View Complete Issue         Table of Contents 2019 
Penpulimab (Anniko) for Nasopharyngeal Carcinoma
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Penpulimab (Anniko) for Nasopharyngeal Carcinoma
June 9, 2025 (Issue: 5112)
Penpulimab-kcqx (Anniko – Akeso Biopharma), a programmed death receptor-1 (PD-1)-blocking antibody, has been approved by the FDA for use in combination with cisplatin or carboplatin plus gemcitabine for first-line treatment of recurrent or...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Penpulimab (Anniko) for Nasopharyngeal Carcinoma
Article code: 5112a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.